Examining new approaches, novel technologies, and the structural evolution of the raw materials market.

Examining Trends in Oral Solid Dosage Manufacturing

Advancements in soft capsule technology can enable the development of soft capsule formulations.

Novel Formulations and Line Extensions with Soft Capsule Technology

Alternative drug delivery formulation strategies can remove some drug dosage forms limitations.

Delivering a Difference in Formulation

Topic

Feliza Mirasol is the science editor for 

Articles

Sandoz, a Novartis division, is expected to invest at least $400 million to build a new biologics manufacturing facility in Lendava, Slovenia, to support growing demand for biosimilars.

Sandoz to Build New Biologics Production Facility in Slovenia

Editor of Pharmaceutical Technology Europe

Podcasts

In this episode, Rhonda Henry and Adam Mendizabal from Emmes discuss the role CROs play in cell and gene therapies undergoing clinical trials at all stages.

Drug Solutions Podcast: How CROs Adapt Themselves in the Ever-Changing Landscape of Cell and Gene Therapies

Pramote Cholayudth previously was the managing director of the Professional Conference Center, Ltd. He currently is a validation consultant to Biolab Co., Ltd., in Thailand. He is the founder and manager of PM consult, cpramote2000@yahoo.com.

This article discusses the evaluation of paired content uniformity and weight variation data sets using F and T tests to ensure that batches meet compendial requirements.

Justification of Using Weight Variation Instead of Content Uniformity for Release of Relevant OSD Forms

Advancements in therapeutic modalities are necessitating change in drug delivery to help negate some of the expense of development and manufacturing.

Influencing Change in Drug Delivery

Bianca Piachaud-Moustakis is lead writer at Pharmavision, Pharmavision.co.uk.

EnteroBiotix is harnessing the power of the microbiome to target an array of diseases.

Frontrunner in Microbiome Therapeutics

Lilly will cap insulin prices for patients with and without insurance at $35 per month.

Eli Lilly to Cap Out-Of-Pocket Insulin Costs at $35

Quotient Sciences’ facility expansion is designed to increase support for fully integrated drug development programs.

Quotient Sciences Expands Formulation Development Capabilities at Nottingham Facility

is an executive director at WuXi Biologics.

Wesley Wang is vice-president at WuXi Biologics.

Weichang Zhou is president at WuXi Biologics.

In this paper, the authors lay out some commonly accepted HCP analytical methods, the challenges of HCP assay, and provide recommendations on what can easily be accomplished in-house and when it may be better to outsource.

Current Trends in Host Cell Protein Detection for Biologics Manufacturing

Shifting toward more technological solutions and ensuring a greater understanding of the workforce’s needs will give both CROs and sponsors a market advantage.

CROs Gaining a Competitive Edge

Suzanne Shelley is contibuting editor to 

Efforts to optimize the delivery of sensitive biotherapeutics continue to evolve.

Dosage Forms

Examining Trends in Oral Solid Dosage Manufacturing

Novel Formulations and Line Extensions with Soft Capsule Technology

Delivering a Difference in Formulation